new_0222_0240|PMVP|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0240|PMVP|1|PMV Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|PMV Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|PMV Pharmaceuticals Inc Inventories (Quarterly) (USD)|PMV Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|PMV Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|PMV Pharmaceuticals Inc Book Value (Quarterly) (USD)|PMV Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|PMV Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|PMV Pharmaceuticals Inc EV to Revenues|PMV Pharmaceuticals Inc EV to Earnings|PMV Pharmaceuticals Inc EV to Free Cash Flow|PMV Pharmaceuticals Inc EV to Assets (Quarterly)|PMV Pharmaceuticals Inc PS Ratio|PMV Pharmaceuticals Inc PE Ratio|PMV Pharmaceuticals Inc Price to Book Value|PMV Pharmaceuticals Inc PEG Ratio|PMV Pharmaceuticals Inc Debt to Equity Ratio|PMV Pharmaceuticals Inc Dividend Yield|PMV Pharmaceuticals Inc Shareholder Yield (TTM)|PMV Pharmaceuticals Inc Percent of Shares Outstanding Short|PMV Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Payables (Quarterly) (USD)|PMV Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|PMV Pharmaceuticals Inc Return on Invested Capital|PMV Pharmaceuticals Inc Quality Ratio Score|PMV Pharmaceuticals Inc Momentum Score|PMV Pharmaceuticals Inc Beta (1Y)|PMV Pharmaceuticals Inc Sustainable Growth Rate (TTM)|PMV Pharmaceuticals Inc Institutional Investor Ownership Percentage|PMV Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|PMV Pharmaceuticals Inc Total Employees (Annual)|PMV Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|PMV Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|PMV Pharmaceuticals Inc Shares Outstanding|PMV Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|PMV Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|PMV Pharmaceuticals Inc Payout Ratio|PMV Pharmaceuticals Inc Quick Ratio (Quarterly)|PMV Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|PMV Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|PMV Pharmaceuticals Inc Effective Tax Rate (TTM)|PMV Pharmaceuticals Inc Return on Equity|PMV Pharmaceuticals Inc Net Income (TTM) (USD)|PMV Pharmaceuticals Inc Revenue (TTM) (USD)|PMV Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|PMV Pharmaceuticals Inc Revenue (Quarterly) (USD)|PMV Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|PMV Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|PMV Pharmaceuticals Inc Net Income (Quarterly) (USD)|PMV Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|PMV Pharmaceuticals Inc Price (USD)|PMV Pharmaceuticals Inc Total Return Price (USD)|PMV Pharmaceuticals Inc Enterprise Value (USD)|PMV Pharmaceuticals Inc 30-Day Average Daily Volume|PMV Pharmaceuticals Inc 1 Year Price Returns (Daily)|PMV Pharmaceuticals Inc Short Interest|PMV Pharmaceuticals Inc PE Ratio (Forward)|PMV Pharmaceuticals Inc PE Ratio (Forward 1y)|PMV Pharmaceuticals Inc PS Ratio (Forward)|PMV Pharmaceuticals Inc PS Ratio (Forward 1y)|PMV Pharmaceuticals Inc Quarterly EPS Estimates (USD)|PMV Pharmaceuticals Inc Quarterly Revenue Estimates (USD)|PMV Pharmaceuticals Inc Quarterly EPS Surprise|PMV Pharmaceuticals Inc Quarterly Revenue Surprise|PMV Pharmaceuticals Inc Quarterly Actual EPS (USD)|PMV Pharmaceuticals Inc Quarterly Actual Revenue (USD)|PMV Pharmaceuticals Inc Revenue Estimates for Current Fiscal Year (USD)|PMV Pharmaceuticals Inc Revenue Estimates for Next Fiscal Year (USD)|PMV Pharmaceuticals Inc Price Target (USD)|PMV Pharmaceuticals Inc Consensus Recommendation|PMV Pharmaceuticals Inc Price Target Num Estimates|PMV Pharmaceuticals Inc EPS Estimates for Current Fiscal Year (USD)|PMV Pharmaceuticals Inc EPS Estimates for Next Fiscal Year (USD)|PMV Pharmaceuticals Inc Research and Development Expense (Quarterly) (USD)|PMV Pharmaceuticals Inc Reconciled Depreciation (Quarterly) (USD)|PMV Pharmaceuticals Inc Non-Operating Interest Expense (Quarterly) (USD)|PMV Pharmaceuticals Inc Land and Improvements (Quarterly) (USD)|PMV Pharmaceuticals Inc Buildings and Improvements (Quarterly) (USD)|PMV Pharmaceuticals Inc Other Properties (Quarterly) (USD)|PMV Pharmaceuticals Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0240|PMVP|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0240|PMVP|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0240|PMVP|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44755244755||||1.44759206799|||1.44759206799||15.25||106.5|106.5|||30.6666666667|30.75|||91.375|104|91.375|91.375|31.6923076923||106.5|||91.375|91.25|91.4||91.4|||||91.375|91.375|91.375|1.44759206799|1.44759206799|1.44759206799|1.45061728395|1.42574257426|15.25|||||91.3333333333|91.3333333333|91.25||91.25|91.25|34.2857142857|34.2857142857|33.5|18.0384615385|33.5|24|28.2352941176|91.375|91.375||||91|106.5||
new_0222_0240|PMVP|6|6|6||6||6|6|6||6|6||||286||||353|||353||32||6|6|||3|4|||8|1|8|8|13||6|||8|4|5||5|||||8|8|8|353|353|353|324|101|32|||||9|9|4||4|4|14|14|14|26|14|20|17|8|8||||3|6||
new_0222_0240|PMVP|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0240|PMVP|201909||||||||||||||||||||||||||||||||||31.2343||-0.1977|1.545||||||-0.1977|||||||||-6.168|-6.175|0.272||||||||||||||||||||||||4.895|0.107|||||||
new_0222_0240|PMVP|201912|102.093|101.486||0.739||173.507|4.523|168.984||-70.474|-75.44|||||||||||||||2.837||||||||31.2343||-0.2256|1.656|||44.7737|||-0.2256|||||||||-7.047|-7.047|0.316||||||||||||||||||||||||5.699|0.095|||||1.915||
new_0222_0240|PMVP|202003||||||||||||||||||||||||||||||||||31.2343||-0.2323|1.699||||||-0.2323|||||||||-7.253|-7.255|0.406||||||||||||||||||||||||5.955|0.094|||||||
new_0222_0240|PMVP|202006|156.757|156.106||0.609||5.147|5.053|0.094||153.895|-90.661|||||||||||||||2.146||||||||42.9993||-0.1853|2.281|||44.7737|||-0.1853||-0.0317||-28.444|||||-7.967|-7.967|0.157||||||||||||||||||||||||5.804|0.088|||||1.967||
new_0222_0240|PMVP|202009|373.672|373.15||0.573||5.476|5.476|||368.97|-99.426||||||||4.3078|||||0.4175||0.548|||||||83.5211|6.0225|39|-1.46|2.709|44.7737||44.7737|||-1.46|-224.541|-0.0161||-31.033|||||-8.761|-8.764|0.04|35.5|35.5|1216.3164|143256.9||186922|||||-0.5||-29.6||-0.648||0.12||45.3333|1.5|3|-1.14|-1.0567|5.992|0.075|||||2.006|35.05|35.24
new_0222_0240|PMVP|202012|364.761|361.422||0.569||6.41|6.41|||359.121|-109.88||||-72.7601||||7.6695|||||4.0012||1.607||||||||44.7778|44|-0.2335|4.32|44.7778||44.7778|||-0.2335|1.365|-0.0174||-34.44|||||-10.453|-10.454|0.048|61.51|61.51|2392.8605|232234.8||1791664|||||-0.67||6.3881||-0.6272||0.06||50.3333|1.5|3|-1.8733|-2.275|6.181|0.061||||0.051|2.006|34.14|37.63
new_0222_0240|PMVP|202103|334.953|331.489||1.525||6.098|5.796|0.302||348.295|-121.482||||-30.3445||||4.2382|||||6.2491||1.252||||||||44.7852||-0.26|4.174|44.8812||44.8812|||-0.26||-0.0206||-38.787|||||-11.598|-11.602|0.128|32.89|32.89|1144.6537|193591.5667||2804685|||||-0.21||-23.8095||-0.26||||61.6667|1.5|3|-1.2033|-1.275|7.5|0.079||||0.927|2.078|33.73|34.4
new_0222_0240|PMVP|202106|323.08|318.349||12.016||18.063|7.504|10.559||337.847|-134.356||||-30.2506||||4.5716|||||7.2009||2.369||||||||45.0701||-0.29|5.386|45.2136||45.2136|||-0.29||-0.0183||-43.694|||||-12.874|-12.874|0.113|34.16|34.16|1226.1476|365828.2667||3255767|||||-0.28||-3.5714||-0.29||||62|1.5|4|-1.16|-1.6133|7.664|0.071||||11.307|2.26|34.01|30.35
new_0222_0240|PMVP|202109|313.555|307.651||11.804||19.23|8.563|10.667||324.948|-149.367||||-22.6928||||4.1591|||||6.6475||1.278||||2|1.4691|||45.2952||-0.33|5.935|45.3522||45.3522|||-0.33||-0.0481||-49.941|||||-14.992|-15.011|0.102|29.8|29.8|1043.8446|414862.0667|-16.0563|3014778|||||-0.298||-10.7383||-0.33||||62.2|1.5714|5|-1.18|-1.68|9.162|0.08||||11.156|2.278|23.62|21.75
new_0222_0240|PMVP|202112|||||||||||||||-16.1011||||3.226|||||8.1602||||||2|0.5763||||||||||||||||||||||||23.1|23.1|740.6362|510045.5|-62.4451|3703118|||||-0.3383||||||||60.8|1.5714|5|-1.56|-1.73||||||||16.06|15.35
new_0222_0240|PMVP|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.355|||||||||||||||||||||
new_0222_0240|PMVP|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.3767|||||||||||||||||||||
new_0222_0240|PMVP|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.41|||||||||||||||||||||
new_0222_0240|PMVP|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.45|||||||||||||||||||||